MA39734A - Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation - Google Patents

Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation

Info

Publication number
MA39734A
MA39734A MA039734A MA39734A MA39734A MA 39734 A MA39734 A MA 39734A MA 039734 A MA039734 A MA 039734A MA 39734 A MA39734 A MA 39734A MA 39734 A MA39734 A MA 39734A
Authority
MA
Morocco
Prior art keywords
therapeutic
manufacturing
therapeutic agent
nanoparticles containing
use methods
Prior art date
Application number
MA039734A
Other languages
English (en)
Other versions
MA39734B1 (fr
Inventor
Shubha Bagrodia
Jennifer LAFONTAINE
Zach Lovatt
Eyoung Shin
Young Ho Song
Greg Troiano
Hong Wang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA39734A publication Critical patent/MA39734A/fr
Publication of MA39734B1 publication Critical patent/MA39734B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne, d'une manière générale, des nanoparticules comprenant un acide sensiblement hydrophobe et un agent thérapeutique (1-(4-{[4-(diméthylamino)pipéridin-1-yl]carbonyl}phényl)-3-[4- (4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phényl]urée), ou des sels pharmaceutiquement acceptables de celui-ci, et un polymère. D'autres aspects concernent des procédés de fabrication et d'utilisation de telles nanoparticules.
MA39734A 2014-03-14 2015-03-13 Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation MA39734B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461953628P 2014-03-14 2014-03-14
PCT/US2015/020343 WO2015138835A1 (fr) 2014-03-14 2015-03-13 Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation

Publications (2)

Publication Number Publication Date
MA39734A true MA39734A (fr) 2017-01-18
MA39734B1 MA39734B1 (fr) 2019-07-31

Family

ID=52780047

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39734A MA39734B1 (fr) 2014-03-14 2015-03-13 Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation

Country Status (42)

Country Link
US (4) US9895378B2 (fr)
EP (2) EP3511019B1 (fr)
JP (2) JP6348616B2 (fr)
KR (1) KR20160126084A (fr)
CN (1) CN106163503B (fr)
AP (1) AP2016009494A0 (fr)
AR (1) AR099756A1 (fr)
AU (2) AU2015229210B2 (fr)
BR (1) BR112016021130A2 (fr)
CA (1) CA2942859A1 (fr)
CL (1) CL2016002308A1 (fr)
CR (1) CR20160477A (fr)
CU (1) CU24488B1 (fr)
CY (1) CY1122078T1 (fr)
DK (2) DK3511019T3 (fr)
DO (1) DOP2016000244A (fr)
EA (1) EA032234B1 (fr)
EC (1) ECSP16081557A (fr)
ES (2) ES2834927T3 (fr)
GE (1) GEP20207083B (fr)
HR (1) HRP20191187T1 (fr)
HU (1) HUE043964T2 (fr)
IL (1) IL247346B (fr)
LT (1) LT3116547T (fr)
MA (1) MA39734B1 (fr)
ME (1) ME03435B (fr)
MX (1) MX2016012009A (fr)
MY (1) MY178189A (fr)
NI (1) NI201600138A (fr)
PE (1) PE20170312A1 (fr)
PH (1) PH12016501794A1 (fr)
PL (1) PL3116547T3 (fr)
PT (1) PT3116547T (fr)
RS (1) RS59035B9 (fr)
SA (1) SA516371814B1 (fr)
SG (1) SG11201607645TA (fr)
SI (1) SI3116547T1 (fr)
SV (1) SV2016005277A (fr)
TW (2) TWI636798B (fr)
UA (1) UA121967C2 (fr)
WO (1) WO2015138835A1 (fr)
ZA (1) ZA201606646B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015088990A1 (fr) 2013-12-09 2015-06-18 Durect Corporation Complexes de principes pharmaceutiquement actifs, complexes de polymères, et compositions et procédés les impliquant
DK3104838T3 (da) 2014-02-13 2020-02-24 Pfizer Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf
KR102472590B1 (ko) 2014-05-14 2022-11-30 타르그이뮨 테라퓨틱스 아게 개선된 폴리에틸렌이민 폴리에틸렌글리콜 벡터
WO2016097949A1 (fr) 2014-12-17 2016-06-23 Pfizer Inc. Formulations d'un inhibiteur de pi3k/mtor pour administration intraveineuse
US11833255B2 (en) * 2015-10-07 2023-12-05 The Brigham And Women's Hospital, Inc. Nanoparticles with pH triggered drug release
RU2018115566A (ru) * 2015-10-30 2019-12-03 Пфайзер Инк. Терапевтические наночастицы, содержащие терапевтический агент, и их способы получения и применения
RU2018133578A (ru) * 2016-03-25 2020-04-27 Пфайзер Инк. Стабильные составы для лиофилизации терапевтических частиц
US10369230B2 (en) 2017-04-06 2019-08-06 National Guard Health Affairs Sustained release of a therapeutic agent from PLA-PEG-PLA nanoparticles for cancer therapy
US11541058B2 (en) 2017-08-25 2023-01-03 Pfizer Inc. Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
EP4249069A3 (fr) * 2018-06-07 2023-11-29 Pfizer Inc. Formulation aqueuse comprenant de la 1-(4-{[4-(diméthylamino)pipéridin-1-yl]carbonyl}phényl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phényl]urée
CN111286204B (zh) * 2020-03-12 2021-08-20 复旦大学 一种遇含水溶剂快速溶解或分散的高分子复合物及其制备方法和应用
RU2751699C1 (ru) * 2020-07-17 2021-07-15 Федеральное казённое учреждение здравоохранения "Ставропольский научно-исследовательский противочумный институт" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ получения наночастиц хитозана с включенным ципрофлоксацином
MX2023004101A (es) 2020-10-08 2023-10-11 Targimmune Therapeutics Ag Inmunoterapia para el tratamiento de cancer.
US20230022525A1 (en) 2021-07-26 2023-01-26 Celcuity Inc. Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
WO2023079142A2 (fr) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Conjugués linéaires ciblés comprenant du polyéthylèneimine et du polyéthylène glycol et polyplexes comprenant ceux-ci
WO2023150246A1 (fr) * 2022-02-04 2023-08-10 Virginia Commonwealth University Formulations à libération prolongée et leurs procédés d'utilisation
WO2024100044A1 (fr) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Polyplexes d'acides nucléiques et conjugués ciblés comprenant de la polyéthylèneimine et du polyéthylène glycol
WO2024100040A1 (fr) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Conjugués linéaires ciblant psma comprenant du polyéthylèneimine et du polyéthylène glycol et polyplexes comprenant ceux-ci
WO2024100046A1 (fr) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Conjugués linéaires ciblés comprenant du polyéthylèneimine et du polyéthylène glycol et polyplexes comprenant ceux-ci
US11833224B1 (en) 2023-02-08 2023-12-05 Leuvian Llc Lyoprotectant compositions and uses thereof

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000846A1 (fr) 1987-07-29 1989-02-09 The Liposome Company, Inc. Procede de separation granulometrique de particules
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
WO1993011785A1 (fr) 1991-12-09 1993-06-24 Asahi Kasei Kogyo Kabushiki Kaisha Composition a base d'hormone parathyroidienne stabilisee
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
CA2207961A1 (fr) 1995-01-05 1996-07-11 Robert J. Levy Nanoparticules a modification de surface et leurs procedes de fabrication et d'utilisation
CA2214889C (fr) 1995-03-10 2005-05-24 Hans Koll Formes galeniques pharmaceutiques contenant un polypeptide, sous forme de microparticules, et leur procede de preparation
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
JP2942508B2 (ja) 1997-01-14 1999-08-30 順也 藤森 温度感受性徐放性基剤及び温度感受性徐放性システム
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6254890B1 (en) 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
AU754003B2 (en) 1998-06-30 2002-10-31 Amgen, Inc. Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents
US6265609B1 (en) 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
KR100274842B1 (ko) 1998-10-01 2001-03-02 김효근 미립구를 이용한 레티노익산의 서방형 약물방출 시스템
DE19856432A1 (de) 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
AU6132700A (en) 1999-09-30 2001-04-05 Chienna B.V. Polymers loaded with bioactive agents
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US20050037086A1 (en) 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
US6890946B2 (en) 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
KR100418916B1 (ko) 2000-11-28 2004-02-14 한국과학기술원 생분해성 고분자와 항암제의 접합체를 이용한 서방형미셀제제의 제조방법
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
AU2002235253A8 (en) 2000-12-21 2005-10-06 Inhale Therapeutic Syst Induced phase transition method for the production of microparticles containing hydrophilic active agents
US6623761B2 (en) 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
PT1345597E (pt) 2000-12-27 2007-10-29 Ares Trading Sa Nanopartículas lipídicas anfifílicas para incorporação de péptidos e/ou proteínas
CA2436408A1 (fr) 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Ligands de la psma modifies et utilisation de ces derniers
AU2002338336A1 (en) 2001-04-03 2002-10-21 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EP1492554B1 (fr) 2001-06-21 2019-08-21 Althea Technologies, Inc. Particules de proteine spheriques
CN1325046C (zh) 2001-08-31 2007-07-11 麦吉尔大学 可生物降解的多聚纳米微囊及其应用
WO2003055469A1 (fr) 2001-12-21 2003-07-10 Celator Technologies Inc. Vecteur ameliore a base de polymere et de lipide
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US7691412B2 (en) 2001-10-10 2010-04-06 Pierre Fabre Medicament Prolonged release biodegradable microspheres and method for preparing same
ES2625340T3 (es) 2001-10-15 2017-07-19 Crititech, Inc. Composiciones y métodos para la administración de fármacos escasamente solubles en agua y métodos de tratamiento
US20030235619A1 (en) 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
WO2003060523A1 (fr) 2002-01-10 2003-07-24 Johns Hopkins University Agents d'imagerie et procedes d'imagerie de naaladase et psma
AU2003227147A1 (en) 2002-04-05 2003-10-27 Universite De Montreal Stealthy polymeric biodegradable nanospheres and uses thereof
US20030232887A1 (en) 2002-04-10 2003-12-18 Johnson Douglas Giles Preparation and use of a stable formulation of allosteric effector compounds
AU2003228666A1 (en) 2002-04-23 2003-11-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
JP2003342168A (ja) 2002-05-24 2003-12-03 Nano Career Kk 注射用薬物含有ポリマーミセル製剤の製造方法
CN100369593C (zh) 2002-06-05 2008-02-20 佛罗里达大学研究基金会有限公司 眼科给药体系
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
US7879351B2 (en) 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
JP2006514698A (ja) 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド ナノ粒子生物活性物質
JP4917263B2 (ja) 2002-12-23 2012-04-18 バイカル インコーポレイテッド 核酸／ブロックコポリマー／陽イオン性界面活性剤複合体を凍結乾燥する方法
US6841547B2 (en) 2003-02-28 2005-01-11 Albert Einstein College Of Medicine Of Yeshevia University Method for decreasing low density lipoprotein
US20040185170A1 (en) 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
DK1610768T3 (da) 2003-03-26 2008-09-22 Egalet As Matrikskompositioner til styret afgivelse af lægemiddelsubstanser
AU2004224530A1 (en) 2003-03-26 2004-10-07 Ltt Bio-Pharma Co., Ltd. Intravenous nanoparticles for targenting drug delivery and sustained drug release
CN102697737B (zh) 2003-04-03 2014-03-19 杰西.L.-S.奥 负载肿瘤靶向药物的颗粒
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050256071A1 (en) 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
CN100588423C (zh) 2003-07-23 2010-02-10 Pr药品有限公司 控释组合物
CA2537057A1 (fr) 2003-09-02 2005-03-10 Novartis Ag Traitement anticancereux utilisant des epothilones
US7311901B2 (en) 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
US7846412B2 (en) 2003-12-22 2010-12-07 Emory University Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof
JP2007526322A (ja) 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
WO2006002365A2 (fr) 2004-06-24 2006-01-05 Angiotech International Ag Microparticules fortement chargees en agent bioactif
CA2571899A1 (fr) 2004-07-01 2006-08-03 Yale University Materiaux polymeres charges de medicaments cibles a forte densite
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
JP2006131577A (ja) 2004-11-09 2006-05-25 Ltt Bio-Pharma Co Ltd 異なる粒子径を有する薬物封入ナノ粒子の作製方法および当該方法で得られたナノ粒子
KR20070104574A (ko) 2004-12-30 2007-10-26 신벤션 아게 신호를 제공하는 제제, 임플란트 재료 및 약물을 포함하는조합물
WO2006093991A1 (fr) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Composes se liant a l'antigene membranaire specifique de la prostate (psma) et utilisations associees
WO2006107957A2 (fr) 2005-04-04 2006-10-12 Sinexus, Inc. Dispositifs et procedes de traitement des affections sinus paranasaux
JP2006321763A (ja) 2005-05-20 2006-11-30 Hosokawa Funtai Gijutsu Kenkyusho:Kk 生体適合性ナノ粒子及びその製造方法
US20110182805A1 (en) 2005-06-17 2011-07-28 Desimone Joseph M Nanoparticle fabrication methods, systems, and materials
RU2436768C2 (ru) 2005-07-11 2011-12-20 Вайет Глютаматы в качестве ингибиторов аггреканазы
AU2006278573A1 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
EP1928435B8 (fr) 2005-08-31 2019-03-20 Abraxis BioScience, LLC Compositions de médicaments faiblement hydrosolubles présentant une stabilité accrué et methode de préparation associé
US8765181B2 (en) 2005-09-09 2014-07-01 Beijing Diacrid Medical Technology Co., Ltd Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids
US20090022806A1 (en) 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US20080267876A1 (en) 2005-09-20 2008-10-30 Yissum Research Development Company Nanoparticles for Targeted Delivery of Active Agent
CA2631714C (fr) 2005-12-02 2014-09-16 Novartis Ag Nanoparticules destinees a etre utilisees dans des compositions immunogenes
US8916206B2 (en) 2005-12-26 2014-12-23 Ltt Bio-Pharma Co., Ltd. Nanoparticles containing water-soluble non-peptide low-molecular weight drug
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20090155349A1 (en) 2006-02-23 2009-06-18 Jonathan Daniel Heller Methods of treating influenza viral infections
DE102006013531A1 (de) 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
WO2008105773A2 (fr) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology Système pour l'administration ciblée d'agents thérapeutiques
EP2019691B1 (fr) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymères pour particules fonctionnelles
JP5373606B2 (ja) 2006-07-26 2013-12-18 サンド・アクチエンゲゼルシヤフト カスポファンギン製剤
RU2476219C2 (ru) 2006-07-31 2013-02-27 Сэндзю Фармасьютикал Ко., Лтд. Жидкая композиция на водной основе, содержащая амидное соединение
WO2008016602A2 (fr) 2006-07-31 2008-02-07 Neurosystec Corporation Formulations médicamenteuses nanoparticulaires
WO2008019142A2 (fr) 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Systèmes oligonucléotidiques pour une administration intracellulaire ciblée
US9248121B2 (en) 2006-08-21 2016-02-02 Abbott Laboratories Medical devices for controlled drug release
KR100946275B1 (ko) 2006-09-26 2010-03-08 주식회사 삼양사 수 난용성 캄토테신 유도체의 미세 나노입자 및 그의제조방법
CN101778910B (zh) 2006-11-08 2014-05-28 分子制药洞察公司 谷氨酸的异质二聚体
US20100303723A1 (en) 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
CN1957911A (zh) 2006-12-01 2007-05-09 济南康泉医药科技有限公司 一种抗实体肿瘤缓释剂
CN101396340A (zh) 2006-12-12 2009-04-01 济南帅华医药科技有限公司 一种含埃坡霉素衍生物的抗癌缓释注射剂
CN1969816A (zh) 2006-12-12 2007-05-30 济南帅华医药科技有限公司 一种含埃坡霉素的抗癌缓释剂
CN101433520A (zh) 2006-12-12 2009-05-20 济南帅华医药科技有限公司 含埃坡霉素的抗癌缓释剂
CN1969818A (zh) 2006-12-12 2007-05-30 济南帅华医药科技有限公司 一种含埃坡霉素衍生物的抗癌缓释注射剂
CN101396342A (zh) 2006-12-12 2009-04-01 济南帅华医药科技有限公司 含埃坡霉素衍生物的抗癌缓释注射剂
CN1961864A (zh) 2006-12-12 2007-05-16 济南帅华医药科技有限公司 一种抗癌的组合物
US20100015050A1 (en) 2006-12-21 2010-01-21 Wayne State University Peg and targeting ligands on nanoparticle surface
KR20090118999A (ko) 2007-03-07 2009-11-18 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
CN101053553B (zh) 2007-03-16 2011-04-20 吉林大学 一种生物可降解氟尿嘧啶聚酯载药纳米球及其制备方法
WO2008124634A1 (fr) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Micelles inverses encapsulées par un polymère
WO2008124639A2 (fr) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Fractions de ciblage de poly (acide aminé)
EP2156848A4 (fr) 2007-05-14 2012-11-28 Ltt Bio Pharma Co Ltd Nanoparticule contenant un médicament de bas poids moléculaire ayant un groupe chargé négativement à libération prolongée
CA2990445C (fr) 2007-08-21 2020-05-05 Board Of Regents, The University Of Texas System Melange thermocinetique pour des applications pharmaceutiques
US20090061009A1 (en) 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
ES2647538T3 (es) 2007-09-28 2017-12-22 Pfizer Inc. Direccionamiento a células de cáncer usando nanopartículas
US20090306120A1 (en) 2007-10-23 2009-12-10 Florencia Lim Terpolymers containing lactide and glycolide
US8974814B2 (en) 2007-11-12 2015-03-10 California Institute Of Technology Layered drug delivery polymer monofilament fibers
WO2009070302A1 (fr) 2007-11-30 2009-06-04 The Johns Hopkins University Nanoparticules ciblees sur l'antigene membranaire specifique de la prostate (psma) utiles dans le traitement du cancer de la prostate
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
WO2009084801A1 (fr) 2007-12-31 2009-07-09 Samyang Corporation Composition micellaire de copolymère à blocs amphiphiles contenant du taxane et son procédé de fabrication
EP2106806A1 (fr) 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticules pour la livraison ciblée d'agents actifs vers les poumons
BRPI0912230A2 (pt) * 2008-05-06 2017-08-22 Glaxo Group Ltd Método para encapsular agentes biologicamente ativos em um carreador particulado, carreador particulado, e, composição farmacêutica
US20090312402A1 (en) 2008-05-20 2009-12-17 Contag Christopher H Encapsulated nanoparticles for drug delivery
CN102036995B (zh) 2008-05-23 2014-09-17 惠氏有限责任公司 作为PI3激酶和mTOR抑制剂的三嗪化合物
PT2774608T (pt) * 2008-06-16 2020-01-17 Pfizer Nanopartículas poliméricas carregadas com fármaco e métodos de produção e utilização das mesmas
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
EP2309991B1 (fr) 2008-06-16 2019-03-06 Pfizer Inc Nanoparticules polymères thérapeutiques comprenant des alcaloïdes vinca et procédés de fabrication et d utilisation associés
CN102099016A (zh) * 2008-06-16 2011-06-15 佰恩德生物科学股份有限公司 载药的聚合物纳米微粒及其制备和使用方法
EP2285350B1 (fr) 2008-06-16 2017-11-15 Pfizer Inc Procédés pour la préparation de copolymères diblocs fonctionnalisés avec un agent de ciblage destinés à être utilisés dans la fabrication de nanoparticules thérapeutiques
CA2728909A1 (fr) 2008-07-08 2010-01-14 Abbott Laboratories Proteines de liaison a la prostaglandine e2 et leurs utilisations
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
US20110125090A1 (en) 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
WO2010075072A2 (fr) 2008-12-15 2010-07-01 Bind Biosciences Longues nanoparticules circulantes pour la libération prolongée d'agents thérapeutiques
WO2010114770A1 (fr) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-agent, particules, compositions et procédés d'utilisation apparentés
CA2756072A1 (fr) 2009-03-30 2010-10-14 Cerulean Pharma Inc. Conjugues polymere-agent, particules, compositions et procedes d'utilisation apparentes
WO2010114768A1 (fr) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Conjugués polymère-épothilone, particules, compositions et procédés d'utilisation apparentés
JP6072539B2 (ja) 2009-05-27 2017-02-01 アルカーメス ファーマ アイルランド リミテッド ナノ粒子活性物質組成物におけるフレーク状凝集の軽減
CA2779843A1 (fr) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, et procedes pour l'identification, l'evaluation, la prevention, et la therapie d'un cancer
ES2721898T3 (es) 2009-12-11 2019-08-06 Pfizer Formulaciones estables para liofilizar partículas terapéuticas
JP6175237B2 (ja) 2009-12-15 2017-08-02 ファイザー・インク コルチコステロイドを含む治療用ポリマーナノ粒およびそれを製造かつ使用する方法
JP5965844B2 (ja) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
EP2512459A4 (fr) 2009-12-15 2013-08-07 Nanoparticules polymères thérapeutiques comportant de l'épothilone et leurs procédés de fabrication et d'utilisation
WO2011079279A2 (fr) 2009-12-23 2011-06-30 Board Of Trustees Of The University Of Illinois Nanoconjugués et compositions de nanoconjugués
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
WO2012040513A1 (fr) 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Compositions et procédés d'administration de bêta-lapachone
EP2629760A4 (fr) 2010-10-22 2014-04-02 Bind Therapeutics Inc Nanoparticules thérapeutiques contenant des copolymères de masse moléculaire élevée
US20140308363A1 (en) 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US20150017245A1 (en) 2011-09-22 2015-01-15 Bind Therapeutics, Inc. Methods of treating cancers with therapeutic nanoparticles
CA2860932C (fr) 2012-01-13 2021-02-16 Magnus Brisander Composition pharmaceutique contenant des nanoparticules hybrides amorphes stables d'au moins un inhibiteur de la proteine kinase et d'au moins un constituant polymere stabilisant et matriciel
EP2819659B1 (fr) 2012-02-29 2018-05-30 Merck Patent GmbH Procédé de fabrication de nanoparticules chargées d'une substance active
KR20150056619A (ko) 2012-09-17 2015-05-26 바인드 쎄라퓨틱스, 인크. 치료제를 포함하는 치료 나노입자 및 그의 제조 및 사용 방법
MX356097B (es) 2012-09-17 2018-05-14 Pfizer Inc Star Proceso para la preparacion de nanoparticulas terapeuticas.
MX2016000131A (es) 2013-06-28 2016-06-15 Bind Therapeutics Inc Nanoparticulas polimericas de docetaxel para el tratamiento de cancer.

Also Published As

Publication number Publication date
PT3116547T (pt) 2019-07-25
TW201620505A (zh) 2016-06-16
BR112016021130A2 (pt) 2017-08-15
GEP20207083B (en) 2020-04-10
EP3116547B1 (fr) 2019-06-05
AP2016009494A0 (en) 2016-10-31
IL247346B (en) 2019-05-30
CN106163503B (zh) 2021-02-26
US10071100B2 (en) 2018-09-11
ES2834927T3 (es) 2021-06-21
US20210177857A1 (en) 2021-06-17
PH12016501794A1 (en) 2016-11-07
US20180125854A1 (en) 2018-05-10
MY178189A (en) 2020-10-06
NI201600138A (es) 2016-10-14
EA201691692A1 (ru) 2017-02-28
HRP20191187T1 (hr) 2019-10-04
ME03435B (fr) 2020-01-20
TWI693937B (zh) 2020-05-21
CR20160477A (es) 2017-02-24
SV2016005277A (es) 2017-03-20
TW201834658A (zh) 2018-10-01
US20150258102A1 (en) 2015-09-17
CL2016002308A1 (es) 2017-05-26
JP2017508803A (ja) 2017-03-30
CU24488B1 (es) 2020-11-30
CY1122078T1 (el) 2020-11-25
DK3511019T3 (da) 2020-10-26
LT3116547T (lt) 2019-07-25
AR099756A1 (es) 2016-08-17
AU2015229210B2 (en) 2019-07-04
PL3116547T3 (pl) 2019-11-29
SI3116547T1 (sl) 2019-08-30
US9895378B2 (en) 2018-02-20
CA2942859A1 (fr) 2015-09-17
RS59035B9 (sr) 2019-11-29
ECSP16081557A (es) 2019-02-28
SG11201607645TA (en) 2016-10-28
AU2015229210A1 (en) 2016-10-06
JP6348616B2 (ja) 2018-06-27
DK3116547T3 (da) 2019-07-15
MX2016012009A (es) 2016-12-05
WO2015138835A1 (fr) 2015-09-17
AU2019240695A1 (en) 2019-10-24
EP3116547A1 (fr) 2017-01-18
EP3511019A1 (fr) 2019-07-17
ES2737692T3 (es) 2020-01-15
IL247346A0 (en) 2016-11-30
KR20160126084A (ko) 2016-11-01
SA516371814B1 (ar) 2019-09-30
EP3511019B1 (fr) 2020-10-14
HUE043964T2 (hu) 2019-09-30
MA39734B1 (fr) 2019-07-31
ZA201606646B (en) 2018-04-25
EA032234B1 (ru) 2019-04-30
JP2018154643A (ja) 2018-10-04
UA121967C2 (uk) 2020-08-25
TWI636798B (zh) 2018-10-01
DOP2016000244A (es) 2017-03-31
RS59035B1 (sr) 2019-08-30
CN106163503A (zh) 2016-11-23
US20180344746A1 (en) 2018-12-06
CU20160135A7 (es) 2017-02-02
PE20170312A1 (es) 2017-03-30

Similar Documents

Publication Publication Date Title
MA39734A (fr) Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12018501920A1 (en) Bromodomain inhibitors
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
MD20160136A2 (ro) Compuşi dihidroizochinolinonici substituiţi
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
WO2016061232A3 (fr) Sharn multiplexés et leurs utilisations
WO2014039903A3 (fr) Formulations aqueuses stables d'adalimumab
BR112015022861A8 (pt) inibidores de bromodomínio
FR2985274B1 (fr) Structures fibreuses comprenant des particules et leur procede de fabrication
CR20200057A (es) Dihidrooxadiazinonas
PH12014502294A1 (en) Triazolo compounds as pde10 inhibitors
CO7151489A2 (es) Forma amorfa de un compuesto de pirimidinilciclopentano, inhibidor akt, composiciones y métodos del mismo
WO2014153459A3 (fr) Hap fluorescente : colorant de diagnostic pour noyaux vhb dans des cellules
MX2014002682A (es) Modulares de la fosfodiesterasa 10 (pde 10).
BR112018013033A2 (pt) compostos de indolinonas e seu uso no tratamentod de doenças fibróticas
BR112015018047A8 (pt) método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
TN2019000114A1 (en) Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof
MX2018010378A (es) Una composicion que comprende pic para el tratamiento del cancer.
BR112019007631A2 (pt) inibidores de bromodomínios
WO2014105777A8 (fr) Sel de dichlohydrate de cobicistat
IN2015DN01518A (fr)
GB2565957A (en) Novel renal disease model